Clinical Trial Update: Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody [Phase 3]

View source ↗

Summary

Phase 3 trial for pre-surgical detection of clear cell renal cell carcinoma using radiolabeled G250-antibody has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• G250-antibody radiolabeled (radiolabeled G250-antibody)

Snippet

Sponsor: Heidelberg Pharma AG | Conditions: Renal Cell Carcinoma, Kidney Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-04-14